NGM-707

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameNGM-707
Drug Alias NameNGM-707
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor B1 inhibitorsLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor B1Leukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck & CoNGM Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNGM Biopharmaceuticals IncMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A